Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, DFTX, ABVX, COGT, ALMS, and represent 55.84% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 9 stocks: ABVX (+$42M), DFTX (+$24M), Erasca (+$23M), SMMT (+$18M), ANL (+$11M), PHVS (+$10M), FTH (+$9.0M), GYRE (+$6.3M), TSHA (+$5.7M).
- Started 5 new stock positions in Erasca, SMMT, FTH, ANL, GYRE.
- Reduced shares in these 10 stocks: Centessa Pharmaceuticals (-$30M), Kalvista Pharmaceuticals (-$29M), TERN (-$28M), TRVI (-$22M), KYMR (-$13M), OCUL (-$11M), DNTH (-$10M), DTIL (-$7.0M), BBOT (-$6.4M), LXEO (-$6.3M).
- Sold out of its positions in BBOT, Centessa Pharmaceuticals, EVMN, CATX, Kalvista Pharmaceuticals, LXEO, TERN.
- Octagon Capital Advisors was a net seller of stock by $-21M.
- Octagon Capital Advisors has $1.1B in assets under management (AUM), dropping by 23.12%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 27 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 16.1 | $180M | -5% | 1.8M | 97.48 |
|
| Definium Therapeutics Com Shs (DFTX) | 12.5 | $139M | +20% | 3.0M | 47.04 |
|
| Abivax Sa Sponsored Ads (ABVX) | 11.9 | $132M | +46% | 993k | 133.26 |
|
| Cogent Biosciences (COGT) | 8.2 | $91M | 2.4M | 38.70 |
|
|
| Alumis (ALMS) | 7.2 | $80M | 2.8M | 28.14 |
|
|
| Arrivent Biopharma (AVBP) | 6.2 | $69M | 2.0M | 34.74 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 5.9 | $66M | +9% | 9.7M | 6.81 |
|
| Bioage Labs (BIOA) | 3.9 | $43M | 1.7M | 24.51 |
|
|
| Mirum Pharmaceuticals (MIRM) | 3.6 | $40M | 339k | 117.07 |
|
|
| Kymera Therapeutics (KYMR) | 3.2 | $36M | -27% | 310k | 114.67 |
|
| Aktis Oncology (AKTS) | 2.8 | $31M | 961k | 32.23 |
|
|
| Xenon Pharmaceuticals (XENE) | 2.7 | $30M | 490k | 60.36 |
|
|
| Erasca Call Call Option | 2.1 | $23M | NEW | 1.3M | 18.32 |
|
| Palisade Bio (PALI) | 1.9 | $22M | 10M | 2.09 |
|
|
| Ocular Therapeutix (OCUL) | 1.8 | $20M | -34% | 2.1M | 9.82 |
|
| Disc Medicine (IRON) | 1.8 | $20M | 270k | 73.14 |
|
|
| Summit Therapeutics (SMMT) | 1.6 | $18M | NEW | 1.3M | 14.57 |
|
| Pharvaris N V (PHVS) | 1.4 | $16M | +176% | 457k | 34.58 |
|
| Adlai Nortye Sponsored Ads (ANL) | 1.0 | $11M | NEW | 935k | 11.50 |
|
| Precision Biosciences Com New (DTIL) | 1.0 | $11M | -39% | 1.4M | 7.86 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.8 | $9.4M | 574k | 16.40 |
|
|
| Faeth Therapeutics Com New (FTH) | 0.8 | $9.0M | NEW | 361k | 25.00 |
|
| Gyre Therapeutics Incorporated (GYRE) | 0.6 | $6.3M | NEW | 954k | 6.59 |
|
| Trevi Therapeutics (TRVI) | 0.5 | $5.9M | -78% | 315k | 18.65 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.4 | $4.7M | 1.0M | 4.69 |
|
|
| Context Therapeutics (CNTX) | 0.2 | $1.7M | -41% | 3.1M | 0.55 |
|
| Gossamer Bio (GOSS) | 0.1 | $1.3M | 7.8M | 0.16 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2026 Q2 filed Aug. 14, 2026
- Octagon Capital Advisors 2026 Q1 filed May 15, 2026
- Octagon Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Octagon Capital Advisors 2025 Q3 filed Nov. 14, 2025
- Octagon Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Octagon Capital Advisors 2025 Q1 restated filed May 16, 2025
- Octagon Capital Advisors 2025 Q1 filed May 15, 2025
- Octagon Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023